Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Cash & Equivalents (2016 - 2026)

Mimedx's Cash & Equivalents history spans 17 years, with the latest figure at $159.8 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 50.12% to $159.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $159.8 million, a 50.12% increase, with the full-year FY2025 number at $166.1 million, up 59.1% from a year prior.
  • Cash & Equivalents hit $159.8 million in Q1 2026 for Mimedx, down from $166.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for MDXG hit a ceiling of $166.1 million in Q4 2025 and a floor of $48.5 million in Q1 2024.
  • Historically, Cash & Equivalents has averaged $94.0 million across 5 years, with a median of $78.8 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: dropped 24.27% in 2022 and later surged 119.5% in 2025.
  • Tracing MDXG's Cash & Equivalents over 5 years: stood at $66.0 million in 2022, then rose by 24.34% to $82.0 million in 2023, then grew by 27.34% to $104.4 million in 2024, then surged by 59.1% to $166.1 million in 2025, then fell by 3.82% to $159.8 million in 2026.
  • Business Quant data shows Cash & Equivalents for MDXG at $159.8 million in Q1 2026, $166.1 million in Q4 2025, and $142.1 million in Q3 2025.